Definium’s DT120 Phase 3 Success Drives 50% Rally and $500M Offering
DFTX•Definium’s Phase 3 EMERGE trial of DT120 showed a 13.3-point MADRS improvement versus 5.2 in placebo among 149 depressed patients, triggering a 50% share gain. The company unveiled a $500 million share and warrant offering while Canaccord and RBC boosted price targets to $60 and $57 on safety and efficacy data.
1. Phase 3 EMERGE Results
The late-stage EMERGE trial enrolled 149 adults with moderate to severe major depressive disorder and tested a single 100-microgram dose of DT120, an orally disintegrating lysergide tablet. Patients showed a 13.3-point average improvement on the MADRS depression scale at six weeks versus 5.2 points for placebo, with benefits evident within one week and sustained through 12 weeks, and no serious safety issues reported.
2. Share Price Reaction
DFTX shares surged 50% in regular trading, marking the best performance since March 2024, before slipping 5% in after-hours on dilution concerns tied to the new offering. The intraday rally reflected strong investor enthusiasm for the rapid antidepressant effect and clean safety profile of DT120.
3. Underwritten Public Offering
Definium filed to sell $500 million of common shares and pre-funded warrants in an underwritten offering to fund ongoing trials and operations. Investors are weighing the capital raise against potential share dilution as the company advances its psychiatric pipeline.
4. Analyst Upgrades and Outlook
Canaccord raised its price target to $60 from $38, citing increased conviction in DT120, while RBC lifted its target to $57 from $36, describing the data as “best-case” efficacy with no new safety signals. Both firms noted that robust major depressive disorder results bode well for upcoming generalized anxiety disorder trial readouts.
